## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.5% in lower entry zone (4.0-10.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (2.7%) confirms momentum alignment. Strong momentum (+2.8% 5-day acceleration). Outperforming sector by 7.8%. Caution: overbought RSI (72).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($49.55)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. CAR T cell therapy patient resources**
- Source: Bristol Myers Squibb | 20251205T230755 | Bullish | Relevance: 100%
- This article from Bristol Myers Squibb provides comprehensive resources for patients considering or undergoing CAR T cell therapy, an innovative treatment for certain blood cancers. It debunks common myths about the therapy, explains the treatment process, compares it to other treatments like chemotherapy and stem cell transplants, and addresses concerns about side effects and cost. The content includes a video interview with a patient and a science communicator, offering personal insights and breaking down the science behind CAR T cell therapy.

**2. Does Bristol Myers Squibb’s Recent Rebound Signal a Compelling Long Term Value Opportunity?**
- Source: Simply Wall Street | 20251205T160731 | Bullish | Relevance: 100%
- Bristol-Myers Squibb's stock has rebounded recently, sparking investor interest in its long-term value. Analysis using Discounted Cash Flow and Price-to-Earnings ratios suggests the company may be significantly undervalued, despite patent expiries and past stock declines. The article encourages investors to explore these valuation methods and consider the company's strategic pipeline and market positioning.

**3. FDA Approves Bristol Myers Squibb’s Breyanzi for Marginal Zone Lymphoma**
- Source: Contract Pharma | 20251205T140824 | Bullish | Relevance: 100%
- The FDA has approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have undergone at least two prior systemic therapies. This marks Breyanzi's fifth FDA approval for cancer types, making it the first and only CAR T cell therapy approved for this specific patient population. The approval is supported by data from the TRANSCEND FL study, showing a 95.5% overall response rate and a 62.1% complete response rate in MZL patients.

**4. Dodge & Cox Has $390.54 Million Stake in Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251205T100731 | Neutral | Relevance: 100%
- Dodge & Cox reduced its stake in Bristol Myers Squibb Company by 35.3% in the second quarter, now owning 8.4 million shares worth $390.54 million. Other hedge funds also adjusted their holdings, with institutional investors owning 76.41% of the company's stock. Bristol Myers Squibb recently reported strong quarterly earnings and a dividend announcement, while analysts maintain a "Hold" consensus rating with an average target price of $55.25.

**5. Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)**
- Source: Bristol Myers Squibb | 20251205T012203 | Bullish | Relevance: 100%
- The U.S. FDA has approved Bristol Myers Squibb's Breyanzi® (lisocabtagene maraleucel; liso-cel) as the first and only CAR T cell therapy for adult patients with relapsed or refractory marginal zone lymphoma (MZL) after at least two prior systemic therapies. This approval, based on the TRANSCEND FL study, demonstrated an overall response rate of 95.5% and a complete response rate of 62.1% in the MZL cohort, with a consistent safety profile. Breyanzi is now approved for five cancer types, solidifying its position as a leading CD19-directed CAR T cell therapy.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $53 | $45 | +18% |
| 2025-12-02 | Goldman Sachs | $57 | $51 | +12% |
| 2025-11-17 | Citigroup | $45 | $48 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Perform |
| 2025-12-02 | Goldman Sachs | main | Neutral |
| 2025-11-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +2.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (2 raises, avg +15%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.2B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.7 |
| Current P/E | 8.0 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 2.7% to 5.5% (+2.8% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 at 2.7% confirms short-term momentum alignment. AM_20 at 7.9% shows strong absolute momentum above own 20MA. Outperforming sector by 7.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 72, risk of mean reversion. Elevated volume (1.5x 20MA), institutional activity likely. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.49% (CS: 86) | Strong |
| RSI_14 | 71.9 | Overbought |
| MACD Histogram | 0.41 | Bullish |
| vs SMA20 | 1.079x | Above |
| vs SMA50 | 1.131x | Above |
| vs SMA200 | 1.062x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $52.15
- **Stop Loss:** $49.55 (5.0% risk)
- **Target:** $56.05 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 192
- **Position Value:** $10,012.80
- **Portfolio %:** 10.01%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*